CNS Pharmaceuticals (NASDAQ:CNSP) Stock Breaks Below Two Hundred Day Moving Average – Time to Sell?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)’s share price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.61 and traded as low as $4.30. CNS Pharmaceuticals shares last traded at $4.51, with a volume of 61,129 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

CNS Pharmaceuticals Stock Down 11.2%

The firm has a market cap of $6.58 million, a price-to-earnings ratio of -0.19 and a beta of 3.10. The stock’s 50 day moving average is $5.36 and its 200 day moving average is $4.61.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new position in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 41,573 shares of the company’s stock, valued at approximately $198,719. Stonepine Capital Management LLC owned approximately 2.85% of CNS Pharmaceuticals at the end of the most recent quarter. Institutional investors own 14.02% of the company’s stock.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for primary and metastatic cancers of the central nervous system. The company is headquartered in Houston, Texas, and its shares trade on the Nasdaq Capital Market under the symbol CNSP.

CNS Pharmaceuticals’ lead product candidate is berubicin, an anthracycline designed to cross the blood-brain barrier. The company is evaluating berubicin as a potential treatment for glioblastoma multiforme, an aggressive and often fatal form of brain cancer for which treatment options remain limited.